Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:17:25.735Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:17:25.735Z.
Quote observation: 2026-10-06T19:10:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2baa5019f568993ecceb1943c30cf17443c8d153a00c2cc4d930c3e59df60e4
FORWARD PE RATIO
N/A
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.12M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.12M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.06M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.03M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.23M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A |
| Imunon, Inc. (IMNN)vs › | $4.96M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.28M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.34M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
